Elizabeth Mittendorf, MD, PhD

Elizabeth Mittendorf, MD, PhD, director of the Breast Oncology Program at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, discusses the importance of identifying biomarkers in patients with breast cancer. Current studies are looking at PD-L1 as a possible biomarker, but Mittendorf believes there may be other biomarkers that will prove to be more reliable. 

Elizabeth Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, discusses discovering a predictive biomarker response in vaccine therapy for patients with breast cancer.

​Elizabeth Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, discusses an upcoming peptide vaccine to prevent recurrence in patients with breast cancer.

Elizabeth Mittendorf, MD, PhD, discusses the use of peptide vaccines for the treatment of breast cancer.

Elizabeth Mittendorf, MD, PhD, from the University of Texas MD Anderson Cancer Center, gives an overview of how the E75 vaccine works in breast cancer.